New Complementary Insulins and GLP-1 Combinations to Achieve HbA1C Targets

Saturday, April 2, 2016 | 6:00 – 8:00 AM EST
Westin Boston Waterfront Hotel, Grand Ballroom

This course is a live CME-certified ancillary symposium presented at ENDO 2016, the Endocrine Society's 98th Annual Meeting and Expo, held in Boston, Massachusetts, April 1–4, 2016. ENDO 2016 ancillary symposia are developed through the Endocrine Society’s Special Programs Committee (SPC). There is no cost to attend, and all ENDO 2016 attendees are welcome; however, seating is limited and advance registration is recommended. You must be registered for ENDO 2016 to attend an ENDO 2016 ancillary symposium.

This activity is supported by an educational grant from sanofi-aventis U.S. Inc.

SYMPOSIUM AGENDA

Opening and Welcome
Program Director: Athena Philis-Tsimikas,MD – Scripps Whittier Diabetes Institute

Standards of Diabetes Care
Jeffrey Sandler, MD – Scripps Mercy Hospital

Challenges Encountered in Optimizing Glucose Management
Daniel Einhorn, MD – Scripps Health

Physiologic Replacement with Insulins and GLP-1 Therapy to Meet Goals
George Dailey, MD – Scripps Clinical Medical Group

A Brief Look at the Future - Biologic Replacement Therapy
Alberto Hayek, MD – University of California, San Diego

Panel Discussion and Interactive Case Presentations

Target Audience

This continuing medical education activity should be of substantial interest to Endocrinologists, internists, endocrine nurses, diabetes educators, researchers, and other allied health professionals

Learning Objectives

Upon completion of this educational activity, learners will be better able to:

  • Assess unmet needs and treatment patterns of patients with type 2 diabetes that are not at target
  • Identify and select appropriate individual glycemic targets tailored to the patient using shared decision making
  • Learn how to select and start new combination options using insulins and GLP-1 that are in development or recently approved to help patients get to goal
  • Gain an understanding of future biologic approaches to treatment
  • Evaluate strategies in the ambulatory setting to mitigate barriers to combination therapy for glucose control

Additional Information

Target Audience: 
Physician-in-practice
Fellow
Resident
Clinical researcher
Scientific researcher
Educator/Teacher
Pharmacist
Nurse/Nurse practitioner
Physician assistant
Allied health professional
Other
Competency Area: 
Patient Care and Procedural Skills
Medical Knowledge
Topic Area: 
Diabetes and Glucose Metabolism
Quality Improvement and Healthcare Delivery
General Endocrinology
Level of Outcomes: 
Level 1 (Participation)
Level 2 (Satisfaction)
Level 3A (Learning: Declarative Knowledge (Knows))
Level 3B (Learning: Procedural Knowledge (Knows How))
Level 4 (Learning: Competence (Shows How))
Level 5 (Performance (Does))
Activity summary
Available credit: 
  • 2.00 AMA PRA Category 1 Credits
  • 2.00 CME Certificate of Participation
Course opens: 
04/02/2016
Course expires: 
04/02/2017
Rating: 
0
Boston, MA 02210
United States

Athena Philis-Tsimikas, MD - Program Director
Corporate Vice President
Scripps Whittier Diabetes Institute—Scripps Health
San Diego, California

George Dailey, MD
Senior Consultant, Scripps Clinic Medical Group
San Diego, California

Daniel Einhorn, MD
Past President, ACE
Scripps Health
La Jolla, California

Alberto Hayek, MD
Professor Emeritus
University of California, San Diego
La Jolla, California

Jeffrey Sandler, MD
Senior Endocrinologist
Scripps Mercy Hospital
San Diego, California

DISCLOSURE POLICY

The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent CME planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.

The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.

The faculty reported the following relevant financial relationship(s) during the content development process for this activity:
Athena Philis-Tsimikas, MD: Advisory Board Member, AstraZeneca, Dexcom, Eli Lilly & Co., Novo Nordisk, Sanofi
Daniel Einhorn, MD: Advisory Board Member, Janssen, Lilly USA, LLC, Takeda
George Dailey, MD: Consultant, Sanofi, Novo Nordisk; Speaker, AstraZeneca; Investigator, Eli Lilly & Co., Lexicon, Novo Nordisk, Sanofi

The following faculty reported no relevant financial relationship(s): Alberto Hayek, MD; Jeffrey Sandler, MD

The following SPC member who planned and reviewed content for this activity reported no relevant financial relationships:
Amy Rothberg, MD: Consultant, Novo Nordisk; Speaker, Takeda Pharmaceuticals

The following SPC Committee members reported relevant financial relationships:
Zahid Ahmad, MD: Consultant, Regeneron; Speaker, Amgen, Genzyme
Sarah Berga, MD: Advisory Board, Agile Therapeutics, Noven Pharmaceuticals, Inc., Watson Pharmaceuticals, Teva Pharmaceuticals Industries, Shionogi, Inc.; Consultant, AHC Media, LLC, Shionogi, Inc.
Paresh Dandona, MD, PhD, FRCP: Consultant and Speaker, AstraZeneca, Bristol Myers Squibb, Janssen, Merck, Novo Nordisk
Irl Hirsch, MD: Consultant, Abbott Laboratories, Johnson & Johnson, Roche Diagnostics, Valeritas; Investigator, Sanofi
E Michael Lewiecki, MD: Consultant, Amgen, Eli Lilly, Merck, Radius Health, AgNovos Healthcare, Theranova; Research Grant Support, Amgen, Eli Lilly, Merck
Lisa Nachtigall, MD: Consultant, Genentech; Consultant and Principal Investigator, Ipsen
Guillermo E Umpierrez, MD, CDE: Advisory Board and Consultant, Abbott, Boehringer Ingelheim, Merck, Novo Nordisk, Regeneron, Sanofi; Research Grant Support, Boehringer Ingelheim, Merck & Co., Novo Nordisk, Regeneron

The following SPC members reported no relevant financial relationships: John Carmichael, MD; Natalie Cusano, MD; Alan Kelly, MD; Larry Fox, MD; Michael S Irwig, MD; Connie B Newman, MD

Endocrine Society and Scripps Health staff associated with the development of content for this activity reported no relevant financial relationships.

Available Credit

  • 2.00 AMA PRA Category 1 Credits
  • 2.00 CME Certificate of Participation

Accreditation Period

Course opens: 
04/02/2016
Course expires: 
04/02/2017